Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLPO49KSzVyPUCuNFYyKM7:TR?= NYr6N3E2W0GQR1XS
ALL-PO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwME[zOVUh|ryP MU\TRW5ITVJ?
697 M{HPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEm5O|Yh|ryP NWf6VJY{W0GQR1XS
NCI-H748 NX7teoVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMUCzN|Qh|ryP NH7OOVZUSU6JRWK=
NKM-1 NXy2VGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33UZWlEPTB;MD6xNFkyOiEQvF2= M3;OUnNCVkeHUh?=
ES1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUGyOVUh|ryP NV;MVWJOW0GQR1XS
NCI-H1963 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMUG1O|kh|ryP NEWxeINUSU6JRWK=
NCI-H1417 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{foeWlEPTB;MD6xNlk4PCEQvF2= NIW3N4RUSU6JRWK=
NEC8 NV\YfldQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETE[GRKSzVyPUCuNVM2OjdizszN NWjOVW1IW0GQR1XS
CRO-AP2 NFvxPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMU[4PFkh|ryP Ml25V2FPT0WU
A3-KAW MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDoeotKSzVyPUCuNVc3OjdizszN MXvTRW5ITVJ?
SF539 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TZW2lEPTB;MD6xPVU6OyEQvF2= Ml3rV2FPT0WU
NOS-1 NXy0THh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zmb2lEPTB;MD6xPVYyQSEQvF2= NW\nOHFGW0GQR1XS
NTERA-S-cl-D1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPhTWM2OD1yLkKwNVE{KM7:TR?= NITKflZUSU6JRWK=
COR-L88 M{Ttbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ocZJEUUN3ME2wMlIzQTV7IN88US=> Mn:0V2FPT0WU
EM-2 NIXEeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMkSwO|kh|ryP M{HWN3NCVkeHUh?=
KARPAS-45 NVH1U3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi1UndVUUN3ME2wMlI4QDN|IN88US=> M4HVRXNCVkeHUh?=
DSH1 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTlcG5CUUN3ME2wMlI5PzB6IN88US=> NWXPR|JwW0GQR1XS
HT-144 M2DQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXlTWM2OD1yLkOwNlU3KM7:TR?= NXHP[5ZqW0GQR1XS
ATN-1 NYPzT4d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf6SXdKSzVyPUCuN|A2PzZizszN M{XrV3NCVkeHUh?=
HEL MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3aTWM2OD1yLkOxN|Q5KM7:TR?= NXvrelZIW0GQR1XS
NB12 NWLFU3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfvTWM2OD1yLkOxO|U3KM7:TR?= NX:4Z5c1W0GQR1XS
LU-139 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;BbWlEPTB;MD6zN|UyKM7:TR?= MWrTRW5ITVJ?
J-RT3-T3-5 NYrIVFdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwM{O3NVYh|ryP M1vqenNCVkeHUh?=
MOLT-13 M{HObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjjPYk2UUN3ME2wMlM{QDFizszN MVfTRW5ITVJ?
SR MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwM{SyOlEh|ryP NFzZPFNUSU6JRWK=
CMK NYHKXpJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjOc3B3UUN3ME2wMlM2PzJ5IN88US=> NIj1SVZUSU6JRWK=
ES8 M13ncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwM{[wNlIh|ryP NEO3eGtUSU6JRWK=
LB647-SCLC M33RXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYexcmhVUUN3ME2wMlM3PzNizszN NIXLe|RUSU6JRWK=
TE-8 NEDtVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwM{[5N|Uh|ryP NVvIOpl6W0GQR1XS
BV-173 NUDkcVk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi2XIkyUUN3ME2wMlM4OTJzIN88US=> M3fEcnNCVkeHUh?=
DEL NInFUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\PTWM2OD1yLkO3OFg4KM7:TR?= MYfTRW5ITVJ?
ARH-77 NHzOPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnkbGRvUUN3ME2wMlM5OTl|IN88US=> NXPTRZc{W0GQR1XS
NCCIT M4nOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uyNmlEPTB;MD6zPFY1QSEQvF2= NFryWmVUSU6JRWK=
RPMI-8402 M1jiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwM{i3NFEh|ryP MmnFV2FPT0WU
MONO-MAC-6 NIDG[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17w[mlEPTB;MD6zPFc4PiEQvF2= MXTTRW5ITVJ?
SK-MM-2 M173XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DJTWlEPTB;MD6zPVg3QCEQvF2= NULuXGQ4W0GQR1XS
CHP-126 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jRdmlEPTB;MD60NFI{OSEQvF2= MX3TRW5ITVJ?
A101D Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu2d3pKSzVyPUCuOFA{KM7:TR?= MUXTRW5ITVJ?
SCH NInLcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwNECzOFIh|ryP NXjxeGlYW0GQR1XS
NMC-G1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDMcXB[UUN3ME2wMlQxOzZ5IN88US=> NFnsdWhUSU6JRWK=
NCI-H209 M1LxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD1yLkSwOlE{KM7:TR?= MmPKV2FPT0WU
MOLT-16 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXrZmhKSzVyPUCuOFExOTdizszN NXnlc3YyW0GQR1XS
RPMI-6666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwNEGxNkDPxE1? NYjhT3UyW0GQR1XS
OPM-2 NX\KXI52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i5NWlEPTB;MD60NVUyOyEQvF2= Mlf2V2FPT0WU
MRK-nu-1 NUPzUIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPkZZdrUUN3ME2wMlQ{OTV|IN88US=> MV3TRW5ITVJ?
BC-1 M{PqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDicZlKSzVyPUCuOFM1ODNizszN NIjieo5USU6JRWK=
MHH-NB-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Vb2F7UUN3ME2wMlQ{PDV|IN88US=> MVrTRW5ITVJ?
Ramos-2G6-4C10 NUn2VXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKze2hUUUN3ME2wMlQ{QDl5IN88US=> NELMSopUSU6JRWK=
LS-513 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNES1NFEh|ryP M3nQdnNCVkeHUh?=
K5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3uTWM2OD1yLkS3NFI2KM7:TR?= MYTTRW5ITVJ?
HOP-62 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7STWM2OD1yLkS4N|U5KM7:TR?= MVLTRW5ITVJ?
NCI-H187 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnORplMUUN3ME2wMlQ6OjJ5IN88US=> NYji[GdLW0GQR1XS
BE-13 NWfsfXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfxTWM2OD1yLkS5OlYyKM7:TR?= NVn3OXpKW0GQR1XS
HC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPHeHBKSzVyPUCuOVA1PzNizszN M4fqOXNCVkeHUh?=
ACN M1z6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwNUGwNlgh|ryP NWjQUVJRW0GQR1XS
HCC1599 NXHMWItDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64fYd4UUN3ME2wMlUyPTdizszN NXrz[lZjW0GQR1XS
MV-4-11 NVP5T5VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrzdY4xUUN3ME2wMlU{ODRzIN88US=> NHLWSpNUSU6JRWK=
LC-2-ad MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNUO2OlMh|ryP Ml;nV2FPT0WU
HL-60 M4\Bemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDTcZJKSzVyPUCuOVQzPjFizszN MmHnV2FPT0WU
NB17 NUK0fW9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPoTWM2OD1yLkW0N|gh|ryP NFvaRoJUSU6JRWK=
TE-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNUWzNFYh|ryP NUn2do81W0GQR1XS
NCI-H524 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrbZIzUUN3ME2wMlU2PDBzIN88US=> Mmf1V2FPT0WU
MZ7-mel NVXwdow3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULnV4I3UUN3ME2wMlU3OTB3IN88US=> M{ezd3NCVkeHUh?=
L-363 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ji[GlEPTB;MD61OlY2PyEQvF2= Mk\vV2FPT0WU
BL-41 NFjhcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmyUVlsUUN3ME2wMlU3QDh7IN88US=> Mo\0V2FPT0WU
LU-134-A NWHGOXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq0TVFKSzVyPUCuOVcxPzNizszN NICxNlhUSU6JRWK=
SIG-M5 M2TaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwNUe4OFgh|ryP MmHHV2FPT0WU
ONS-76 M{LCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDNbFdyUUN3ME2wMlU5OjR{IN88US=> Ml7tV2FPT0WU
KARPAS-299 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTld4wxUUN3ME2wMlU5PTB2IN88US=> M1jPXXNCVkeHUh?=
DU-4475 MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Lb2lEPTB;MD61PFcxOyEQvF2= NH;GcXVUSU6JRWK=
NB69 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rhNWlEPTB;MD61PVgzPSEQvF2= NGTMbFhUSU6JRWK=
MHH-PREB-1 NH\qbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHEZVV[UUN3ME2wMlYxPzF7IN88US=> NITlXZdUSU6JRWK=
LU-165 NHzxUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\DWWdKSzVyPUCuOlE5OTJizszN MYTTRW5ITVJ?
LOUCY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LpeWlEPTB;MD62N|M3PCEQvF2= NV\jNYNjW0GQR1XS
NCI-H526 NWLrXG16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HuZmlEPTB;MD62N|U1OSEQvF2= NHzjWYNUSU6JRWK=
KE-37 NXH5dGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ac29KSzVyPUCuOlQzPzZizszN MUXTRW5ITVJ?
NALM-6 MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrOTWM2OD1yLk[0PFYh|ryP MV3TRW5ITVJ?
CW-2 NXfEN3JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LVOWlEPTB;MD62OVc6PCEQvF2= MknBV2FPT0WU
SU-DHL-1 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwNkW5OFch|ryP MWTTRW5ITVJ?
NB13 NGjuXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjFRVFtUUN3ME2wMlY3QDF5IN88US=> NG\4SYJUSU6JRWK=
QIMR-WIL M3nQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\uTWM2OD1yLk[4N|Q{KM7:TR?= MljuV2FPT0WU
ECC12 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPETWM2OD1yLkewNFg3KM7:TR?= NUjvbJVbW0GQR1XS
KALS-1 NFztPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwN{C0PVIh|ryP NF3jb2xUSU6JRWK=
COR-L279 M4HifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXizcIZRUUN3ME2wMlcxQTl4IN88US=> MomzV2FPT0WU
NB14 M{LUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD1[GxKSzVyPUCuO|I3OTdizszN NXjOdo45W0GQR1XS
CCRF-CEM NHHUOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7TTWM2OD1yLke0OlYyKM7:TR?= NF3jOItUSU6JRWK=
SW954 M1TncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfocoJkUUN3ME2wMlc2QTl7IN88US=> M4LucXNCVkeHUh?=
IST-SL1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XoOGlEPTB;MD63O|M1QCEQvF2= MljXV2FPT0WU
LAMA-84 NYDQW3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DmO2lEPTB;MD63O|U3PyEQvF2= MVvTRW5ITVJ?
Daudi MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDGZnpKSzVyPUCuO|c3QDFizszN MXjTRW5ITVJ?
BC-3 NFvDO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\mR2lEPTB;MD63PFMxQCEQvF2= MljkV2FPT0WU
HCC2998 M2fUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvCTWM2OD1yLke4N|Yh|ryP MlLvV2FPT0WU
NCI-H69 NVHzVGJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwOECxOFch|ryP NHrrfpFUSU6JRWK=
CPC-N MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwOEC1NlQh|ryP MnfsV2FPT0WU
NOMO-1 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHJTWM2OD1yLkixNFg1KM7:TR?= NVnjT2RDW0GQR1XS
CESS NVzCdZNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnWbpNKSzVyPUCuPFEyQTdizszN NWThTlFVW0GQR1XS
LC4-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jhS2lEPTB;MD64OFAxPyEQvF2= NFjke4pUSU6JRWK=
BL-70 NYTPVJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT5[I9KSzVyPUCuPFU4ODJizszN NUH3fJhoW0GQR1XS
ES4 NHz2OZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;2ZVMyUUN3ME2wMlg2QDZ6IN88US=> NYPNXoE6W0GQR1XS
HCE-T NXv2cYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwOEexO|Eh|ryP Mmr2V2FPT0WU
JAR NEDRcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuz[JpKSzVyPUCuPFc5OjdizszN Mn;6V2FPT0WU
ST486 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfDcVNKSzVyPUCuPFc6OTdizszN MYXTRW5ITVJ?
KS-1 M3PwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfKN3BKSzVyPUCuPFgxQTZizszN NXnpT5l4W0GQR1XS
GDM-1 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXw[o5RUUN3ME2wMlg5Pjh5IN88US=> NGnxUlFUSU6JRWK=
EHEB NELOO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwOUK1PFUh|ryP NFyzNZVUSU6JRWK=
LB2518-MEL NFe4c2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfK[mNKSzVyPUCuPVMzQDRizszN NFv3c3JUSU6JRWK=
GOTO NW\2cpkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PiZmlEPTB;MD65OVA4PiEQvF2= MlfYV2FPT0WU
LXF-289 NUHxdmQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK3TWM2OD1yLkm1PVAyKM7:TR?= MXzTRW5ITVJ?
ES6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPj[WV3UUN3ME2wMlk3PDN5IN88US=> NFqxd4ZUSU6JRWK=
OS-RC-2 NGX1OJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TqWGlEPTB;MD65Olg{KM7:TR?= NUnwN4NIW0GQR1XS
DMS-153 M4PN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXQTWM2OD1yLkm3OFY6KM7:TR?= MlHFV2FPT0WU
SK-PN-DW NIGyfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOUe4N|Eh|ryP MmPXV2FPT0WU
HH NWL4fWN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPBTWM2OD1yLkm4PVU6KM7:TR?= MVnTRW5ITVJ?
SH-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7tTWM2OD1zLkCyOFEh|ryP NVTwRWVqW0GQR1XS
MOLT-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDPTWM2OD1zLkCzOFU1KM7:TR?= MmL4V2FPT0WU
TGW NUCx[Y86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm4TWM2OD1zLkC3Olc2KM7:TR?= NH2wN3lUSU6JRWK=
L-540 NFyzRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TRTWlEPTB;MT6xNFYxPCEQvF2= MWPTRW5ITVJ?
PF-382 NYGxfYlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jQcWlEPTB;MT6xNVUyOyEQvF2= MnPiV2FPT0WU
LC-1F MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHriZ2VKSzVyPUGuNVIxODdizszN NXPBO2hiW0GQR1XS
OVCAR-4 NUPETmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO3PXB2UUN3ME2xMlE{OTZ3IN88US=> NHvXNYVUSU6JRWK=
A4-Fuk MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3VTWM2OD1zLkG1N|Y1KM7:TR?= MlrrV2FPT0WU
HCC2218 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3MU2RKSzVyPUGuNVY3PDFizszN NX7s[ZJrW0GQR1XS
HAL-01 NUOzNFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHzb25KSzVyPUGuNVY6PDNizszN NE\GcGhUSU6JRWK=
IST-MEL1 Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr1TWM2OD1zLkG3OlU6KM7:TR?= MkPXV2FPT0WU
NCI-H719 M3TTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwMUe4PVgh|ryP MmfrV2FPT0WU
EVSA-T MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPmTWM2OD1zLkG4NVE1KM7:TR?= MVjTRW5ITVJ?
SK-NEP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGixd3pKSzVyPUGuNlAzPjZizszN Mo\mV2FPT0WU
OCUB-M M3;uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;vPWlEPTB;MT6yNVQ5QSEQvF2= NITrcmxUSU6JRWK=
MEG-01 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DEd2lEPTB;MT6yNlEyQCEQvF2= MkXvV2FPT0WU
no-10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwMkOxNVIh|ryP NEnvVGpUSU6JRWK=
MHH-CALL-2 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LNVmlEPTB;MT6yOFczOSEQvF2= NEHXdotUSU6JRWK=
SK-N-DZ NIDLclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[0c5g4UUN3ME2xMlI1Pzd4IN88US=> NWrBTWRKW0GQR1XS
SCLC-21H NIri[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PI[GlEPTB;MT6yOlQ4QCEQvF2= NVH3cYlIW0GQR1XS
CTV-1 NGrXOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYroXWJvUUN3ME2xMlI4PDJ3IN88US=> MWXTRW5ITVJ?
NB1 NFPrRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjMPJJKSzVyPUGuNlc4OzJizszN NHfqN2tUSU6JRWK=
NCI-H64 NIDaVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfVTWM2OD1zLkK4OFYzKM7:TR?= NIL1Z4tUSU6JRWK=
MDA-MB-134-VI M4jQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX0SJliUUN3ME2xMlI5PTd5IN88US=> M{C5c3NCVkeHUh?=
LB2241-RCC M{SxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3QeFNXUUN3ME2xMlI5PjZ|IN88US=> NE[1TI5USU6JRWK=
8-MG-BA NUXicXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXUdYwzUUN3ME2xMlI5QDZ4IN88US=> MWPTRW5ITVJ?
LP-1 NVvKS|JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D3VmlEPTB;MT6yPVk1PyEQvF2= NFzQU2dUSU6JRWK=
LS-411N M1jSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLjVHdKSzVyPUGuN|A6QThizszN NH;6SFJUSU6JRWK=
CAL-148 NYK2VG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwM{K1OFIh|ryP MXHTRW5ITVJ?
NCI-H2171 NVXnOFc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ZUGFKSzVyPUGuN|Q2ODJizszN MmS5V2FPT0WU
JiyoyeP-2003 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwM{WzPUDPxE1? MoPmV2FPT0WU
NCI-H2107 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LWRmlEPTB;MT6zOVg5OyEQvF2= MmKyV2FPT0WU
BB30-HNC MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrTPVhNUUN3ME2xMlM5QTd6IN88US=> NH25Z4hUSU6JRWK=
K-562 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHiTWM2OD1zLkO5NlE6KM7:TR?= MonQV2FPT0WU
PSN1 NG\zR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLXTWM2OD1zLkSyNlg4KM7:TR?= MnrpV2FPT0WU
HCC2157 M1zRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUKzeIdmUUN3ME2xMlQzPjlzIN88US=> NXj3cI86W0GQR1XS
SBC-1 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3qcGhFUUN3ME2xMlQzPzRzIN88US=> M1PqenNCVkeHUh?=
MC116 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7Md2kzUUN3ME2xMlQ{PjF3IN88US=> NU\yb3BRW0GQR1XS
KARPAS-422 NHXTVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjte3lKSzVyPUGuOFU{PThizszN NVnmNmVkW0GQR1XS
LB996-RCC MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu5TWM2OD1zLkS3NVA{KM7:TR?= NX60PHZ1W0GQR1XS
MSTO-211H NV7QfI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrQTWM2OD1zLkS3PVg4KM7:TR?= M4HwfXNCVkeHUh?=
BT-474 M{PWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnDNXdCUUN3ME2xMlUyPzZ2IN88US=> MV7TRW5ITVJ?
A388 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfVZYNGUUN3ME2xMlUyQTR3IN88US=> NFfqSIJUSU6JRWK=
SJSA-1 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwNUKyOkDPxE1? NWnse25qW0GQR1XS
COLO-829 M4jUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXqfVFvUUN3ME2xMlU{PTZ2IN88US=> NXfk[ZI{W0GQR1XS
KM-H2 NHPocG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzXbVU4UUN3ME2xMlU3PjdizszN M376b3NCVkeHUh?=
GR-ST NXLKT45WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLsT2xKSzVyPUGuOVY5OiEQvF2= MYPTRW5ITVJ?
RPMI-8866 M3;yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwNkCxOFQh|ryP NXvVS2xVW0GQR1XS
KG-1 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXUZVdzUUN3ME2xMlYyQTBzIN88US=> NUX6eZJNW0GQR1XS
NCI-H82 M4HFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfndIlKSzVyPUGuOlM1ODZizszN NV\afVdkW0GQR1XS
LB1047-RCC Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnmdXRKSzVyPUGuOlM1PTlizszN MlzjV2FPT0WU
KM12 NULQU4xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zSfmlEPTB;MT62OFch|ryP MnfUV2FPT0WU
NB5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwNkW2O|ch|ryP MUHTRW5ITVJ?
HDLM-2 NULYVIRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7MRmJKSzVyPUGuOlgzQDFizszN NWjvcHBbW0GQR1XS
KU812 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrSZZFZUUN3ME2xMlY6PjB3IN88US=> NILWd4FUSU6JRWK=
DB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvFW2FlUUN3ME2xMlcxOzV|IN88US=> M2SzeXNCVkeHUh?=
HD-MY-Z MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq4TWM2OD1zLke1NlM1KM7:TR?= MmrJV2FPT0WU
KURAMOCHI MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:xVZNSUUN3ME2xMlc4OjB5IN88US=> MYXTRW5ITVJ?
ETK-1 NUT5RZRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[1UVl3UUN3ME2xMlc5QDd7IN88US=> MkLnV2FPT0WU
SK-UT-1 NIX6bnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwN{mzPFgh|ryP MVvTRW5ITVJ?
HUTU-80 NVPlfHdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[xTWM2OD1zLke5OVA5KM7:TR?= MWHTRW5ITVJ?
ES7 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rQOWlEPTB;MT64NFMxOiEQvF2= NXfRTnpOW0GQR1XS
SW872 NXv6ZYQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HpeGlEPTB;MT64NVM6PSEQvF2= Mni0V2FPT0WU
TK10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr4WHFKSzVyPUGuPFMyODhizszN M4rkNHNCVkeHUh?=
LB831-BLC NYjGe|JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfEdXpKSzVyPUGuPFM2PjNizszN NGmwbWhUSU6JRWK=
TE-9 NHfHSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDHTWM2OD1zLki0OFIzKM7:TR?= MWfTRW5ITVJ?
MLMA M1TSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFexRVBKSzVyPUGuPFgzOzRizszN MVfTRW5ITVJ?
D-542MG Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwOEmzO|Mh|ryP MoPRV2FPT0WU
EW-16 NY\UZYQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;1N2lEPTB;MT65NlczKM7:TR?= MlvtV2FPT0WU
LOXIMVI NIHoOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof0TWM2OD1zLkmzNlgh|ryP MoHmV2FPT0WU
GB-1 M3jacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fnWmlEPTB;MT65N|g3PiEQvF2= NXj5b|FHW0GQR1XS
IST-SL2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Hwb2lEPTB;Mj6wNFI3OiEQvF2= M1zIcXNCVkeHUh?=
LAN-6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nFdmlEPTB;Mj6wNVk3PiEQvF2= NFH4RWpUSU6JRWK=
NCI-H510A NFzXVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofMTWM2OD1{LkC0OVAzKM7:TR?= NV;ud3huW0GQR1XS
NCI-H1092 NFu3NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon5TWM2OD1{LkC1NVI1KM7:TR?= NF3mRlJUSU6JRWK=
HT M{nYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDXOYlbUUN3ME2yMlExPDV2IN88US=> NXPJ[XBbW0GQR1XS
RL95-2 NXHL[HpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrSTWM2OD1{LkGxOFgzKM7:TR?= NFzzXWNUSU6JRWK=
NCI-H1355 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXflO49MUUN3ME2yMlEyPzl{IN88US=> M{D2XXNCVkeHUh?=
NCI-H720 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOwXYtFUUN3ME2yMlE3QDd|IN88US=> NY[wZ2dRW0GQR1XS
NCI-H1522 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqyXFV5UUN3ME2yMlIyPzJ|IN88US=> MY\TRW5ITVJ?
LB373-MEL-D M3O1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X6TmlEPTB;Mj6yOlkxOiEQvF2= NEP3[mNUSU6JRWK=
DG-75 M4TlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwMkexOFgh|ryP M{nXbXNCVkeHUh?=
ML-2 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXsemdKSzVyPUKuN|I5PTVizszN NF3yPVBUSU6JRWK=
SF126 M2HuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfuTWM2OD1{LkOzNFk1KM7:TR?= NEXaXnVUSU6JRWK=
MPP-89 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXyVVNKSzVyPUKuN|MyPDVizszN NHXmb3VUSU6JRWK=
NCI-H345 NV;GZYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJwM{OyO|ch|ryP MnTWV2FPT0WU
LS-123 NWqyOWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPmTWM2OD1{LkO0PVM3KM7:TR?= NIXtN|JUSU6JRWK=
NB10 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnySItHUUN3ME2yMlQyODl{IN88US=> NHPncVNUSU6JRWK=
CGTH-W-1 NYrFZohQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTwWpdKSzVyPUKuOFIzPjdizszN M2D3enNCVkeHUh?=
CP66-MEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTtNpBkUUN3ME2yMlQ4PzdizszN MVvTRW5ITVJ?
L-428 NWTySmN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJwNEi1NlEh|ryP NETjfWhUSU6JRWK=
DMS-79 NVz5b3l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTob4JjUUN3ME2yMlU1OTB|IN88US=> MV;TRW5ITVJ?
NCI-H1882 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwNke1OlIh|ryP NWnlfphZW0GQR1XS
KGN NEKyR|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LRXmlEPTB;Mj63Olg4PiEQvF2= MVLTRW5ITVJ?
EW-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXKZXNKSzVyPUKuO|cxQDNizszN MojPV2FPT0WU
U-266 M4X6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W2[2lEPTB;Mj64OFgzOyEQvF2= Mn\uV2FPT0WU
COLO-320-HSR NYLGcFV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\E[GlEPTB;Mj64OVY1OSEQvF2= MYrTRW5ITVJ?
KMOE-2 NWrzVVliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwOEe3NVEh|ryP NXjwU3NWW0GQR1XS
BB49-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL0TWM2OD1{LkmyOFgh|ryP MoPNV2FPT0WU
GI-1 NXjycFRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LGU2lEPTB;Mj65Nlk2PyEQvF2= MVzTRW5ITVJ?
NCI-H1304 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzFTWM2OD1|LkCwOVEyKM7:TR?= MnrQV2FPT0WU
NCI-H2227 NYfhU3BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmraTWM2OD1|LkCyNFc6KM7:TR?= NVXITlFJW0GQR1XS
U-87-MG M3S1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvFPYpKSzVyPUOuNFM2OTNizszN MVTTRW5ITVJ?
NCI-H747 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37Uc2lEPTB;Mz6wOVIxPiEQvF2= NYL4Wo57W0GQR1XS
CTB-1 M{TT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwMEWzO|Yh|ryP MnfKV2FPT0WU
RPMI-8226 NULvO2JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XqfGlEPTB;Mz6xOFM4QCEQvF2= M1PiOnNCVkeHUh?=
NCI-H2141 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPcWlEPTB;Mz6xOlU3PiEQvF2= MU\TRW5ITVJ?
IST-MES1 NFjxbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\MeZFDUUN3ME2zMlE5Ojd7IN88US=> Mn20V2FPT0WU
TE-5 M2fKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfCNYxKSzVyPUOuNlE{PDJizszN MYTTRW5ITVJ?
UACC-257 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzmTWM2OD1|LkSzOlU6KM7:TR?= NIjHcmpUSU6JRWK=
SK-N-FI NF3VWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH5d3NKSzVyPUOuOFUzOjdizszN M325R3NCVkeHUh?=
MFH-ino M{LzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXkTWM2OD1|LkS2OVg6KM7:TR?= M{fOfXNCVkeHUh?=
SF268 NYj5V21PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XlT2lEPTB;Mz60PFE4PCEQvF2= MmT6V2FPT0WU
TE-12 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;jTWM2OD1|LkWxOlk6KM7:TR?= MXnTRW5ITVJ?
NB6 NV63O|BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT6TWM2OD1|LkW1OVY{KM7:TR?= Mn7ZV2FPT0WU
DJM-1 NVjtVmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNwNUm4PVkh|ryP NIjMVmdUSU6JRWK=
MZ1-PC M2rvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r3WmlEPTB;Mz62NVYzPCEQvF2= MVLTRW5ITVJ?
OCI-AML2 NFziO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrFRYIyUUN3ME2zMlYzPjdzIN88US=> M4XqNHNCVkeHUh?=
NCI-H1155 NWDWXHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrvb2NHUUN3ME2zMlcxQTR5IN88US=> M2[w[3NCVkeHUh?=
RKO NYHrcG1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwN{exPFkh|ryP MYLTRW5ITVJ?
ECC4 NFLmN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPdmpKSzVyPUOuPVcyQTVizszN NYHFTIxiW0GQR1XS
BB65-RCC M2[xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M324ZWlEPTB;Mz65O|U1PyEQvF2= Mle5V2FPT0WU
EB-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmwZZNvUUN3ME2zMlk6PjN|IN88US=> MUTTRW5ITVJ?
SHP-77 M{nYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTDSZk6UUN3ME20MlAxPTJ2IN88US=> MmfIV2FPT0WU
NCI-H2196 M{fj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwMEW2NlUh|ryP MkK3V2FPT0WU
GI-ME-N MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknvTWM2OD12LkC2N|k6KM7:TR?= NUTUNYl6W0GQR1XS
MN-60 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXIXnZpUUN3ME20MlExQDdizszN NWO5dXBUW0GQR1XS
NCI-H1694 NW\S[2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fnemlEPTB;ND6xN|QxPSEQvF2= M3HwfHNCVkeHUh?=
LU-65 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrVTWM2OD12LkG1N|MzKM7:TR?= NVfGXmN1W0GQR1XS
NCI-H1436 NVzxfJp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXB[YJKSzVyPUSuNVg{OzNizszN MYLTRW5ITVJ?
KINGS-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHBV2FSUUN3ME20MlMyPDN{IN88US=> MljHV2FPT0WU
GT3TKB MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPRTWM2OD12LkOzNlY5KM7:TR?= NE\KU3NUSU6JRWK=
Becker NXLyUnJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwM{ezNVIh|ryP Mn\xV2FPT0WU
HCC1187 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GzZ2lEPTB;ND64PVY2PyEQvF2= M3rOTnNCVkeHUh?=
D-502MG M3W5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC3TWM2OD13LkCwOFE3KM7:TR?= M3LXSnNCVkeHUh?=
VA-ES-BJ MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jpZmlEPTB;NT6xN|c4QCEQvF2= MULTRW5ITVJ?
NB7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PpSmlEPTB;NT6xOFEyOiEQvF2= MWnTRW5ITVJ?
SW962 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDyTWhKSzVyPUWuN|g5OTRizszN NYnhOmRyW0GQR1XS
no-11 M{\iNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj5PVRqUUN3ME21Mlc3OzR|IN88US=> M4XVOnNCVkeHUh?=
KNS-81-FD NU\FOmJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq3TWM2OD13LkmwOlk1KM7:TR?= MoCwV2FPT0WU
COLO-684 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH5TWM2OD13Lkm5OFk1KM7:TR?= NHPHOXVUSU6JRWK=
D-263MG NUDafmh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{joTmlEPTB;Nj6wPFg6PSEQvF2= MlKwV2FPT0WU
EW-24 NGDjV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfiTWM2OD14LkK4OVEh|ryP M3e2U3NCVkeHUh?=
TE-10 NH[3XHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHnTWM2OD14LkSyOlI{KM7:TR?= M2DNN3NCVkeHUh?=
EKVX MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTZwNE[zNlEh|ryP Ml;MV2FPT0WU
NCI-H1648 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe1cXFyUUN3ME22MlY4PTV5IN88US=> NXvhflB7W0GQR1XS
LB771-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XsfGlEPTB;Nj65NlMxOSEQvF2= NGDCZnFUSU6JRWK=
SK-MEL-1 M2L6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIexe45KSzVyPUiuNVMyPjZizszN MlvCV2FPT0WU
COLO-668 M1HwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwMke3PFYh|ryP NHXPZlBUSU6JRWK=
EW-12 M4Hx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRThwNEC4NFMh|ryP NVHUSJRVW0GQR1XS
A253 NWTGWIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHaPJR4UUN3ME24Mlg1PjZzIN88US=> Mn\5V2FPT0WU
NCI-H2126 NEXSUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGwS3NCUUN3ME24Mlg6OzF7IN88US=> Mn60V2FPT0WU
Calu-6 M1z0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M174cmlEPTB;OD65PVA1OiEQvF2= NFL2PYJUSU6JRWK=
NCI-H23 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTlwMUe3OFYh|ryP NIXvOXZUSU6JRWK=
WSU-NHL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHKXnRKSzVyPUmuO|c1PzhizszN NHT4S4ZUSU6JRWK=
MMAC-SF NYGyVmtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnye3VKSzVyPUmuPVc6ODRizszN MYHTRW5ITVJ?
SK-LMS-1 M1vYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O5cmlEPTB;MUCuNlg{PCEQvF2= M2qzWXNCVkeHUh?=
GCIY NF\3OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTifHlXUUN3ME2xNE42QTJ2IN88US=> NIr1RVZUSU6JRWK=
TE-15 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\SXHpKSzVyPUGxMlYxODRizszN NV\5RXdDW0GQR1XS
EoL-1-cell Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3joR2lEPTB;MUGuO|Y5OiEQvF2= M{mwUnNCVkeHUh?=
NCI-H2081 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFzLke3PFYh|ryP MmLZV2FPT0WU
EW-3 NUTCbZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2flcWlEPTB;MUKuNlQ3OyEQvF2= Ml;HV2FPT0WU
CAS-1 M2HTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF{LkO2N|Eh|ryP MmLPV2FPT0WU
C2BBe1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomyTWM2OD1zMj62NVMyKM7:TR?= NGHsSZVUSU6JRWK=
D-247MG M1SyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nnb2lEPTB;MUKuO|k2OiEQvF2= MVvTRW5ITVJ?
NCI-SNU-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF{LkiwNVMh|ryP NWTBPZdxW0GQR1XS
LS-1034 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K3XWlEPTB;MUSuN|k4PSEQvF2= NYf1S|hjW0GQR1XS
EW-18 NFfKRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C2dGlEPTB;MUSuOFQ5KM7:TR?= NVP0cplYW0GQR1XS
Raji MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLr[2dKSzVyPUG0MlUxPDlizszN NVrVR5hIW0GQR1XS
D-283MED MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nrVmlEPTB;MUSuOlI4OSEQvF2= M3j1NHNCVkeHUh?=
MZ2-MEL NEXVemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H1[2lEPTB;MUSuPVY6PiEQvF2= M13aOnNCVkeHUh?=
NCI-SNU-16 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnXTIxKSzVyPUG1MlQ3OzNizszN NUXuZlBYW0GQR1XS
P30-OHK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF5Lke4N|Eh|ryP M3rZdHNCVkeHUh?=
RXF393 NVn3V2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjUTWM2OD1zOT6wNVg3KM7:TR?= NEi1bY1USU6JRWK=
NCI-H1395 NV3HOpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX1TWM2OD1{MD62O|A{KM7:TR?= NIrTXI5USU6JRWK=
U-698-M MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXhTWM2OD1{MD63NFc2KM7:TR?= MVLTRW5ITVJ?
NCI-SNU-1 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITzRXJKSzVyPUKwMlczOjNizszN NUn0b4E{W0GQR1XS
SW684 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJzLkG3NVYh|ryP MmCzV2FPT0WU
NCI-H716 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXWYFQUUN3ME2yNU4{OTV2IN88US=> NGDUbY9USU6JRWK=
JVM-2 NVrERpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4OxVGlEPTB;MkGuOFE{OyEQvF2= M2W0bnNCVkeHUh?=
NCI-H1581 M{KxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLCTWM2OD1{Mj60NVQ5KM7:TR?= Ml3yV2FPT0WU
CA46 M1PzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHmZlFXUUN3ME2zNU43QTN4IN88US=> MXrTRW5ITVJ?
SNB75 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17CbGlEPTB;M{OuOlUxOyEQvF2= NYrsd41bW0GQR1XS
KNS-42 NVO3cWRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm3SpNKSzVyPUO1Mlk3OjRizszN M2nob3NCVkeHUh?=
TUR NUnM[ZZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rxV2lEPTB;M{[uNFUzOSEQvF2= NGfodZhUSU6JRWK=
REH NITBO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz0Om9XUUN3ME2zO{45OjFzIN88US=> MVfTRW5ITVJ?
EW-22 NFK4[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jteWlEPTB;NEKuNlg5PSEQvF2= M3jWbHNCVkeHUh?=
NCI-H446 NXXGbWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXsUWxKSzVyPUSyMlc5PTNizszN M1OyVHNCVkeHUh?=
ES3 NEL5TohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW4[5hKSzVyPUSzMlE{OzlizszN MVfTRW5ITVJ?
EW-11 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M162SWlEPTB;NESuPFIyQCEQvF2= NVrKNnZYW0GQR1XS
RH-1 NITRfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLNXI1uUUN3ME20O{42QDF{IN88US=> MUDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

Related Antibodies

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID